Match Document Document Title Score
8173625 Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine  
A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic...
94
4061742 Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors with PGA compounds  
There is disclosed concomitant systemic administration of certain prostaglandins of the PGE-type and PGA-type, for example, 16,16-dimethyl-PGE2 of 16,16-dimethyl-PGA2, and a prostaglandin...
94
US20050260283 Composition for prevention and treatment of colon adenomas  
The present invention provides a composition capable of reducing the risk of colon adenoma formation. This composition will be useful for the prevention and treatment of colon cancer through the...
94
US20040192785 Inhibition of TNF-alpha-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
94
US20080312323 Inhibition of TNF-alpha-Initiated Response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
94
US20020132847 Inhibition of TNF-alpha-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
94
US20080081838 Inhibition of TNF-alpha-Initiated Neutrophil Response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
94
US20020143069 Inhibition of TNF-alpha-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
94
7419960 Hemiterpene glycosides with anti-platelet aggregation activities from Ilex pubescens  
Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of these hemiterpenes...
94
US20060154877 Hemiterpene glycosides with anti-platelet aggregation activities from Ilex pubescens  
Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of these hemiterpenes...
94
8173632 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same  
The invention provides a process for preparing non-crystalline organic compositions and non-crystalline, co-amorphous blends of organic compounds.
93
2063556 Tablet dispensing box  
The invention relates to new and useful improvements in article dispensing containers and more particularly to a container for medicinal tablets such as aspirin tablets. An object of the invention...
93
9132191 Compositions and methods of preventing or ameliorating abnormal thrombus formation and cardiovascular disease  
The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased...
93
US20160303138 Combination Therapy Of Substituted Oxazolidinones  
The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor...
92
US20100120718 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES  
The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor...
92
8247460 Method of treatment for muscular dystrophy  
The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a...
92
US20160206660 COMPOSITION OF STEM CELLS HAVING HIGHLY EXPRESSED FAS LIGAND  
This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed Fas-L. This...
91
3627875 ANTIPYRETIC AND INFLAMMATION COMBATTING COMPOSITIONS  
Compositions having antipyretic and inflammation-reducing activity which employ enzymes.
91
9844599 Nitric oxide releasing produgs of therapeutic agents  
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The...
91
9504678 Oral dosage forms including an antiplatelet agent and an acid inhibitor  
The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor.
91
US20110059521 DEVICE AND METHOD FOR MONITORING INHIBITION OF PLATELET FUNCTION  
The invention provides a method of monitoring the response of platelets to a cyclooxygenase-1 (COX1) inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood...
90
US20110293713 PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS  
Aspects of the present application relate to pharmaceutical formulations comprising a nonsteroidal anti-inflammatory drug, together with a proton pump inhibitor drug, to reduce the incidence of...
89
US20120045505 FIXED DOSE DRUG COMBINATION FORMULATIONS  
Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the...
89
US20170348383 NOVEL COMBINATION AND USE  
The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen,...
89
US20050261245 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The...
88
4970233 Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)  
There is disclosed a method of treating inflammatory viral infections of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV virus and Acquired Immunodeficiency Syndrome (AIDS) Related Complex...
87
7199154 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The...
87
8816083 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof  
The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-α-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel...
86
5687841 Combination shipping container, mixing and drinking vessel  
In combination with an alkaline and aspirin combination compound the improvement of a package which serves as both a shipping container for an individual dosage of such medication and at least one...
86
US20150320792 REMEDY FOR GASTRITIS AND GASTRIC ULCER  
Provided is a gastritis and gastric ulcer-treating agent, which is prepared and developed by processing solar salt and bamboo tree into heat-treated purple salt, in which the heat-treated salt,...
86
US20170119838 REMEDY FOR GASTRITIS AND GASTRIC ULCER  
Provided is a gastritis and gastric ulcer-treating agent, which is prepared and developed by processing solar salt and bamboo tree into heat-treated purple salt, in which the heat-treated salt,...
86
9895409 Remedy for gastritis and gastric ulcer  
Provided is a gastritis and gastric ulcer-treating agent, which is prepared and developed by processing solar salt and bamboo tree into heat-treated purple salt, in which the heat-treated salt,...
86
8911752 Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity  
A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible...
85
5770215 Multivitamin/vascular occlusion inhibiting composition  
The present invention relates to a vitamin supplement containing from 5% to 1000% of the RDA of vitamins and a therapeutically effective amount of a vascular occlusion inhibiting compound which is...
85
US20120082634 TREATMENT FOR DYSLIPIDEMIA  
The present invention relates to compounds, and compositions, useful for treating dyslipidemia.
84
US20070045134 Aqueous Solution of an Analgesic and a Dispenser Therefor  
A bottle cap is adapted to retain a quantity of an additive, such as for example aspirin or the like. The additive is retained in an isolated condition within a sealed chamber or within a bladder...
84
4004002 Anti-inflammatory agents coprecipitated with ligno-sulfonic acid  
Coprecipitates of anti-inflammatory agents and lignosulfonic acid which retain the therapeutic activity of the anti-inflammatory agent and which prevent irritation of the gastric mucosa are...
84
5508031 Method for treating biological damage using a free-radial scavenger and interleukin-2  
Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical...
84
5667776 Treatment for biological damage using tumor necrosis factor and a free-radical scavenger  
Damage to cells, tissue and other body parts in a mammalian host may be treated by using a tumor necrosis factor in conjunction with at least one biological modifier, which may be a free radical...
84
US20120122816 COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION  
The invention relates to reducing, preventing or reversing organ damage, reducing and/or preventing stem cell damage and/or death, enhancing organ preservation and/or survival, or enhancing stem...
84
9023402 Method for treating a mammal by administration of a compound having the ability to release CO  
Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases...
84
US20110237546 METHOD FOR TREATING A MAMMAL BY ADMINISTRATION OF A COMPOUND HAVING THE ABILITY TO RELEASE CO  
Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases...
84
7964220 Method for treating a mammal by administration of a compound having the ability to release CO  
Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases...
84
6469035 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid  
The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid...
83
US20060024335 Oral compositions which mask the bitter taste of a bitter-tasting agent  
An oral composition containing a bitter-tasting agent, such as for example, dextromethorphan, chlorhexidine, guaifenesin, pseudoephedrine, caffeine, peroxide, atorvastatin, aspirin, acetaminophen,...
83
US20020031562 Recovery of gaultherin from plants  
The present invention provides methods for obtaining gaultherin, a natural salicylate derivative, from plant tissue. The methods involve preventing the hydrolysis of the gaultherin in the plant...
83
4757060 Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers  
A pharmaceutical composition and process for administering non-steroidal drugs which are protected against injury to the gastrointestinal tract by a combination of certain H1 and H2 receptor blockers.
83
US20090036412 Methods and Compositions for Inhibition of Angiogenesis  
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs,...
83
8906894 Methods for preventing and treating thrombotic disorders  
Compositions and methods for anti-thrombotic and antiplatelet therapy in a subject are provided. Administration of an MAO-B inhibitor results in reduced platelet aggregation or reversion of...
83
US20140094519 LIPOXIN ANALOGS AS NOVEL INHIBITORS OF ANGIOGENESIS  
The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as...
83


Search
« search again